ArticleCurrent hypertension reports2007
Sarcolemmal fatty acid transport in normal and diseased hearts.
Article in Current hypertension reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Chronic ethanol consumption increases cardiomyocyte fatty acid uptake and decreases ventricular contractile function in C57BL/6J mice.Journal of molecular and cellular cardiology · 2013Article
- Role of FAT/CD36 in novel PKC isoform activation in heart of spontaneously hypertensive rats.Molecular and cellular biochemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our knowledge about the regulation of myocardial fatty acid uptake has increased dramatically in the past decade. Fatty acid uptake was found to occur by a mechanism resembling that of cellular glucose uptake. Thus, following an acute stimulus--particularly insulin or muscle contraction--specific fatty acid transporters translocate from intracellular stores to the plasma membrane to facilitate fatty acid uptake, just like these same stimuli recruit glucose transporters to increase glucose uptake. Studies in humans and in animal models have implicated dysregulation of fatty acid transporters in disease pathogenesis, such as the progression of obesity to insulin resistance and diabetic cardiomyopathy. As a result, membrane fatty acid transporters are now regarded as a promising therapeutic target to rectify abnormalities in cardiac fatty acid use in chronic cardiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.